Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 460 across all filing types
Latest filing 2021-01-13 Capital/Financing Update
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
PLACING OF EXISTING SHARES TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a placing of existing shares and a top-up subscription of new shares under a general mandate. It details the agreement terms, placing price, subscription conditions, use of proceeds, and shareholding changes. The content focuses on fundraising activities, share issuance, and capital structure changes. There are no financial statements or detailed financial performance data, so it is not an Annual Report or Interim Report. It is not a regulatory certification or voting result announcement. The document is a detailed update on capital raising and share issuance activities, fitting the Capital/Financing Update category.
2021-01-13 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions for the month ended 31/12/2020. The content focuses on changes in the company's capital structure, including share issuance, repurchases, and related confirmations. There is no indication of financial performance data, earnings, management commentary, or regulatory certifications. The document is a regulatory filing reporting monthly share capital movements to the stock exchange, consistent with capital/financing updates or share capital changes. Given the detailed nature of share capital movements and the monthly frequency, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is not a brief announcement but a substantive report on capital changes.
2021-01-06 English
DISCLOSEABLE TRANSACTION SUBSCRIPTION OF SHARES IN EYEPOINT PHARMACEUTICALS, INC.
Capital/Financing Update Classification · 95% confidence The document is an announcement by Ocumension Therapeutics regarding a discloseable transaction involving the subscription of shares in EyePoint Pharmaceuticals, Inc. It details the terms of the share purchase agreement, consideration, voting agreement, lock-up, participation rights, registration rights, completion conditions, reasons and benefits of the acquisition, and financial information about EyePoint. The document references compliance with Hong Kong Listing Rules Chapter 14 for discloseable transactions, indicating it is a regulatory announcement about a capital investment transaction. It does not contain financial statements or detailed financial performance data of the company itself, nor is it a full annual or interim report. It is not a call transcript, audit report, or management report. The content focuses on a financing/capital transaction (subscription of shares) and related governance agreements. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2021-01-04 English
VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN THE PHASE III CLINICAL TRIAL OF OT-1001 (ZERVIATE) IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the enrollment of the first patient in a Phase III clinical trial for a product (OT-1001). It is an update on business progress and clinical development, not a financial report, regulatory filing, or meeting material. The document is relatively short (3758 characters) and does not contain financial statements, voting results, or management changes. It is clearly an announcement of a business development event. Therefore, it fits best under the category of a general regulatory announcement or business update, which corresponds to Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2020-12-29 English
VOLUNTARY ANNOUNCEMENT OT-401 APPROVED FOR REAL WORLD STUDY IN HAINAN BOAO
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the approval of their product OT-401 for a real world study in Hainan Boao. It is a business update informing shareholders and potential investors about a significant milestone related to product development and regulatory progress. The document is relatively short (3255 characters) and does not contain financial statements, detailed financial analysis, or regulatory filings such as annual or quarterly reports. It is not an earnings release, capital update, or management report. It is clearly an announcement of a business development event rather than a formal report or filing. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and business updates that do not fit other categories.
2020-12-28 English
CHANGE OF ADDRESS OF HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN THE PRC
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors of Ocumension Therapeutics regarding a change of the company's head office and principal place of business address in the PRC. It is a brief notice without any financial data, regulatory certifications, or detailed report content. It does not relate to financial results, management changes, voting results, or capital structure changes. It is a general regulatory announcement about company information. Given the content and length (1493 characters), it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2020-12-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.